173 related articles for article (PubMed ID: 32403071)
1. Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation.
Nemieboka B; Sharma SK; Rao TD; Edwards KJ; Yan S; Wang P; Ragupathi A; Piersigilli A; Spriggs DR; Lewis JS
Nucl Med Biol; 2020; 86-87():9-19. PubMed ID: 32403071
[TBL] [Abstract][Full Text] [Related]
2. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS
J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339
[TBL] [Abstract][Full Text] [Related]
3. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.
Dharma Rao T; Park KJ; Smith-Jones P; Iasonos A; Linkov I; Soslow RA; Spriggs DR
Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):462-72. PubMed ID: 20453816
[TBL] [Abstract][Full Text] [Related]
4. ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.
Sharma SK; Mack KN; Piersigilli A; Pourat J; Edwards KJ; Keinänen O; Jiao MS; Zhao H; White B; Brooks CL; de Stanchina E; Madiyalakan MR; Hollingsworth MA; Radhakrishnan P; Lewis JS; Zeglis BM
Clin Cancer Res; 2022 Mar; 28(5):948-959. PubMed ID: 34907079
[TBL] [Abstract][Full Text] [Related]
5. Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer.
Mack KN; Samuels ZV; Carter LM; Viray TD; Mandleywala K; Brooks CL; Hollingsworth MA; Radhakrishnan P; Lewis JS
J Nucl Med; 2024 Apr; 65(4):580-585. PubMed ID: 38485271
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
Aithal A; Junker WM; Kshirsagar P; Das S; Kaur S; Orzechowski C; Gautam SK; Jahan R; Sheinin YM; Lakshmanan I; Ponnusamy MP; Batra SK; Jain M
PLoS One; 2018; 13(4):e0193907. PubMed ID: 29708979
[TBL] [Abstract][Full Text] [Related]
7. Generation and characterization of a monoclonal antibody to the cytoplasmic tail of MUC16.
Gipson IK; Mandel U; Menon B; Michaud S; Tisdale A; Campos D; Clausen H
Glycobiology; 2017 Oct; 27(10):920-926. PubMed ID: 28673046
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for antibody recognition of the proximal MUC16 ectodomain.
Lee K; Perry K; Xu M; Veillard I; Kumar R; Rao TD; Rueda BR; Spriggs DR; Yeku OO
J Ovarian Res; 2024 Feb; 17(1):41. PubMed ID: 38374055
[TBL] [Abstract][Full Text] [Related]
9. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract][Full Text] [Related]
10. Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16.
Casey NP; Kleinmanns K; Forcados C; Gelebart PF; Joaquina S; Lode M; Benard E; Kaveh F; Caulier B; Helgestad Gjerde C; García de Jalón E; Warren DJ; Lindemann K; Rokkones E; Davidson B; Myhre MR; Kvalheim G; Bjørge L; McCormack E; Inderberg EM; Wälchli S
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604812
[TBL] [Abstract][Full Text] [Related]
11. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
[TBL] [Abstract][Full Text] [Related]
12. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models.
Chen Y; Clark S; Wong T; Chen Y; Chen Y; Dennis MS; Luis E; Zhong F; Bheddah S; Koeppen H; Gogineni A; Ross S; Polakis P; Mallet W
Cancer Res; 2007 May; 67(10):4924-32. PubMed ID: 17510422
[TBL] [Abstract][Full Text] [Related]
13. Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies.
Tu HF; Wong M; Tseng SH; Ingavat N; Olczak P; Notarte KI; Hung CF; Roden RBS
J Ovarian Res; 2024 Jan; 17(1):19. PubMed ID: 38225646
[TBL] [Abstract][Full Text] [Related]
14. Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth.
Rao TD; Fernández-Tejada A; Axelrod A; Rosales N; Yan X; Thapi S; Wang A; Park KJ; Nemieboka B; Xiang J; Lewis JS; Olvera N; Levine DA; Danishefsky SJ; Spriggs DR
ACS Chem Biol; 2017 Aug; 12(8):2085-2096. PubMed ID: 28617578
[TBL] [Abstract][Full Text] [Related]
15. A novel monoclonal antibody to a defined peptide epitope in MUC16.
Marcos-Silva L; Ricardo S; Chen K; Blixt O; Arigi E; Pereira D; Høgdall E; Mandel U; Bennett EP; Vakhrushev SY; David L; Clausen H
Glycobiology; 2015 Nov; 25(11):1172-82. PubMed ID: 26201951
[TBL] [Abstract][Full Text] [Related]
16. Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer.
Lakatos K; González G; Hoballah J; Brooker J; Jeong S; Evans C; Krauledat P; Hansen WP; Elias KM; Patankar M; Fülöp V; Konstantinopoulos PA; Cramer DW
J Ovarian Res; 2022 Feb; 15(1):28. PubMed ID: 35219339
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Liu JF; Moore KN; Birrer MJ; Berlin S; Matulonis UA; Infante JR; Wolpin B; Poon KA; Firestein R; Xu J; Kahn R; Wang Y; Wood K; Darbonne WC; Lackner MR; Kelley SK; Lu X; Choi YJ; Maslyar D; Humke EW; Burris HA
Ann Oncol; 2016 Nov; 27(11):2124-2130. PubMed ID: 27793850
[TBL] [Abstract][Full Text] [Related]
18. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
Crawford A; Haber L; Kelly MP; Vazzana K; Canova L; Ram P; Pawashe A; Finney J; Jalal S; Chiu D; Colleton CA; Garnova E; Makonnen S; Hickey C; Krueger P; DelFino F; Potocky T; Kuhnert J; Godin S; Retter MW; Duramad P; MacDonald D; Olson WC; Fairhurst J; Huang T; Martin J; Lin JC; Smith E; Thurston G; Kirshner JR
Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217340
[TBL] [Abstract][Full Text] [Related]
19. A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing.
Wang CW; Weaver SD; Boonpattrawong N; Schuster-Little N; Patankar M; Whelan RJ
Cancer Res Commun; 2024 Jan; 4(1):253-263. PubMed ID: 38197671
[TBL] [Abstract][Full Text] [Related]
20. Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence-Coupled Biopanning Platform.
Frietze KM; Roden RB; Lee JH; Shi Y; Peabody DS; Chackerian B
Cancer Immunol Res; 2016 Feb; 4(2):157-64. PubMed ID: 26589767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
